CU23526B6 - Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética - Google Patents

Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética

Info

Publication number
CU23526B6
CU23526B6 CU20060192A CU20060192A CU23526B6 CU 23526 B6 CU23526 B6 CU 23526B6 CU 20060192 A CU20060192 A CU 20060192A CU 20060192 A CU20060192 A CU 20060192A CU 23526 B6 CU23526 B6 CU 23526B6
Authority
CU
Cuba
Prior art keywords
peripheral nerves
restoration
diabetic neuropathy
morfofunctional
manifestations
Prior art date
Application number
CU20060192A
Other languages
English (en)
Inventor
Montequin Jose Ignasio Fernandez
Martinez Vivian Maria Saez
Vera Danay Cibrian
Acosta Jorge Amador Berlanga
Gomez Raimundo Ubieta
Del Barco Herrera Diana Garcia
Blanco Sonia Gonzalez
Nieto Gerardo Enrique Guillen
Martinez Luis Saturnino Herrera
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23526(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20060192A priority Critical patent/CU23526B6/es
Priority to DK07817382.0T priority patent/DK2075004T3/da
Priority to PCT/CU2007/000018 priority patent/WO2008040260A1/es
Priority to EP07817382A priority patent/EP2075004B1/en
Priority to RU2009116646/15A priority patent/RU2460536C2/ru
Priority to CA2665117A priority patent/CA2665117C/en
Priority to US12/443,837 priority patent/US8642552B2/en
Priority to JP2009530751A priority patent/JP5508853B2/ja
Priority to MX2009003678A priority patent/MX2009003678A/es
Priority to CN2007800422158A priority patent/CN101573130B/zh
Priority to AT07817382T priority patent/ATE544462T1/de
Priority to PT07817382T priority patent/PT2075004E/pt
Priority to BRPI0719816A priority patent/BRPI0719816B8/pt
Priority to ARP070104350A priority patent/AR063088A1/es
Priority to PL07817382T priority patent/PL2075004T3/pl
Priority to KR1020097009188A priority patent/KR101464208B1/ko
Priority to ES07817382T priority patent/ES2386058T3/es
Priority to AU2007304640A priority patent/AU2007304640B2/en
Priority to CL200702862A priority patent/CL2007002862A1/es
Priority to ZA200902311A priority patent/ZA200902311B/xx
Publication of CU23526B6 publication Critical patent/CU23526B6/es
Priority to US14/140,849 priority patent/US9034826B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención es aplicable en medicina humana, y se relaciona con un método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética de tipo sensitivo motora, dolorosa; y las manifestaciones de neuritis isquémica, mediante la infiltración del Factor de Crecimiento Epidérmico (del inglés Epidermal Growth Factor, abreviado EGF). También incluye una composición que comprende EGF, el que puede ser formulado junto a anestésicos o analgésicos, o encapsulado en microesferas; que se administra mediante infiltración en la periferia de troncos y/o ganglios neviosos, para la restauración morfofuncional de nervios periféricos en la neuropatía sensitivo-motora, dolorosa, así como las manifestaciones de neuritis isquémica.
CU20060192A 2006-10-03 2006-10-03 Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética CU23526B6 (es)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CU20060192A CU23526B6 (es) 2006-10-03 2006-10-03 Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
AU2007304640A AU2007304640B2 (en) 2006-10-03 2007-10-01 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
AT07817382T ATE544462T1 (de) 2006-10-03 2007-10-01 Verwendung des epidermalen wachstumsfaktors zur morphofunktionellen wiederherstellung von peripheren nerven bei diabetischer neuropathie
BRPI0719816A BRPI0719816B8 (pt) 2006-10-03 2007-10-01 uso do fator de crescimento epidérmico (egf) humano para preparar uma composição farmacêutica injetável para a restauração morfofuncional de nervos periféricos em neuropatia diabética e a referida composição
EP07817382A EP2075004B1 (en) 2006-10-03 2007-10-01 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
RU2009116646/15A RU2460536C2 (ru) 2006-10-03 2007-10-01 Применение эпидермального фактора роста для морфофункционального восстановления периферических нервов при диабетической невропатии
CA2665117A CA2665117C (en) 2006-10-03 2007-10-01 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
US12/443,837 US8642552B2 (en) 2006-10-03 2007-10-01 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
JP2009530751A JP5508853B2 (ja) 2006-10-03 2007-10-01 糖尿病性神経障害における末梢神経の形態機能的回復のための上皮増殖因子の使用
MX2009003678A MX2009003678A (es) 2006-10-03 2007-10-01 Uso del factor de crecimiento epidermico para la restauracion morfofuncional de nervios perifericos en la neuropatia diabetica.
CN2007800422158A CN101573130B (zh) 2006-10-03 2007-10-01 表皮生长因子用于在糖尿病性神经病中外周神经的形态功能恢复的用途
DK07817382.0T DK2075004T3 (da) 2006-10-03 2007-10-01 Anvendelse af epidermal vækstfaktor til morphofunktionel genoprettelse af perifere nerver ved diabetisk neuropati
PT07817382T PT2075004E (pt) 2006-10-03 2007-10-01 Uso de fator de crescimento epidérmico na restauração morfofuncional de nervos periféricos na neuropatia diabética
PCT/CU2007/000018 WO2008040260A1 (es) 2006-10-03 2007-10-01 Uso del factor de crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
ARP070104350A AR063088A1 (es) 2006-10-03 2007-10-01 Uso del factor de crecimiento epidermico para la restauracion morfofuncoional de nervios perifericos en la neuropatia diabetica
PL07817382T PL2075004T3 (pl) 2006-10-03 2007-10-01 Zastosowanie naskórkowego czynnika wzrostu do odbudowy morfofunkcjonalnej nerwów obwodowych w neuropatii cukrzycowej
KR1020097009188A KR101464208B1 (ko) 2006-10-03 2007-10-01 당뇨성 신경병증에서 말초 신경의 형태기능의 복원을 위한 상피 성장인자의 용도
ES07817382T ES2386058T3 (es) 2006-10-03 2007-10-01 Uso del factor del crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
CL200702862A CL2007002862A1 (es) 2006-10-03 2007-10-03 Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
ZA200902311A ZA200902311B (en) 2006-10-03 2009-04-02 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
US14/140,849 US9034826B2 (en) 2006-10-03 2013-12-26 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060192A CU23526B6 (es) 2006-10-03 2006-10-03 Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética

Publications (1)

Publication Number Publication Date
CU23526B6 true CU23526B6 (es) 2010-05-19

Family

ID=38925545

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060192A CU23526B6 (es) 2006-10-03 2006-10-03 Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética

Country Status (20)

Country Link
US (2) US8642552B2 (es)
EP (1) EP2075004B1 (es)
JP (1) JP5508853B2 (es)
KR (1) KR101464208B1 (es)
CN (1) CN101573130B (es)
AR (1) AR063088A1 (es)
AT (1) ATE544462T1 (es)
AU (1) AU2007304640B2 (es)
BR (1) BRPI0719816B8 (es)
CA (1) CA2665117C (es)
CL (1) CL2007002862A1 (es)
CU (1) CU23526B6 (es)
DK (1) DK2075004T3 (es)
ES (1) ES2386058T3 (es)
MX (1) MX2009003678A (es)
PL (1) PL2075004T3 (es)
PT (1) PT2075004E (es)
RU (1) RU2460536C2 (es)
WO (1) WO2008040260A1 (es)
ZA (1) ZA200902311B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101252740B1 (ko) * 2011-05-25 2013-04-11 연세대학교 산학협력단 센서 및 센싱방법
EP2737895A1 (en) * 2012-11-30 2014-06-04 Praxis Pharmaceutical, S.A. Microparticles with EGF, method of preparation and use
US20150320861A1 (en) * 2012-12-21 2015-11-12 Sykehuset Sørlandet Hf Egfr targeted therapy of neurological disorders and pain
EP3035903B1 (en) 2013-08-20 2018-08-22 Anutra Medical, Inc. Syringe fill system and method
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． 粘度低下物質を含有する、多糖および核酸の調合薬
RU2585421C1 (ru) * 2014-12-24 2016-05-27 Артур Владимирович Маргасов Способ восстановления поврежденного нерва

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
SE9601243D0 (sv) 1996-03-29 1996-03-29 Hans Arne Hansson Promotion of regeneration of organized tissues
WO1999036513A1 (en) * 1998-01-20 1999-07-22 Aurx, Inc. A herpes virus vector
US6444205B2 (en) * 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
SE9804064D0 (sv) 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
EP1169052B1 (en) * 1999-04-15 2005-07-20 Caritas St. Elizabeth's Medical Center of Boston, Inc. Vegf angiogenic growth factors for treatment of peripheral neuropathy
AU2001281254A1 (en) * 2000-08-10 2002-02-18 Pharmacia Corporation A new egf motif repeat protein obtained from a cdna library from hs-5 stromal cell line
CU23157A1 (es) 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP2006152001A (ja) * 2001-03-12 2006-06-15 Institute Of Gene & Brain Science 神経損傷の治療薬
CA2441434A1 (en) * 2001-03-12 2002-09-19 Institute Of Gene And Brain Science Remedies for nerve damages
CU23043A1 (es) * 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
US7465463B2 (en) * 2002-09-04 2008-12-16 Polyheal, Ltd. Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues
WO2004084819A2 (en) * 2003-03-19 2004-10-07 University Of Kentucky Research Foundation Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres
EP2289526B1 (en) * 2003-04-25 2014-06-11 The University of Pittsburgh Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration.
JP2008509093A (ja) * 2004-08-06 2008-03-27 ノヴォザイムズ グロペップ リミテッド 糖尿病治療法
JP2009500001A (ja) 2005-01-21 2009-01-08 ノースウエスタン ユニバーシティ 細胞の封入のための方法および組成物
KR100765496B1 (ko) * 2005-12-09 2007-10-10 경희대학교 산학협력단 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물

Also Published As

Publication number Publication date
EP2075004B1 (en) 2012-02-08
AU2007304640B2 (en) 2013-01-17
BRPI0719816B8 (pt) 2021-05-25
CL2007002862A1 (es) 2008-05-23
PT2075004E (pt) 2012-05-02
WO2008040260A1 (es) 2008-04-10
RU2009116646A (ru) 2010-11-10
JP2010505773A (ja) 2010-02-25
US9034826B2 (en) 2015-05-19
ZA200902311B (en) 2010-04-28
US20140105990A1 (en) 2014-04-17
KR20090103862A (ko) 2009-10-01
BRPI0719816B1 (pt) 2018-04-24
CA2665117C (en) 2015-04-14
PL2075004T3 (pl) 2012-09-28
US20100136062A1 (en) 2010-06-03
CA2665117A1 (en) 2008-04-10
CN101573130B (zh) 2012-10-31
JP5508853B2 (ja) 2014-06-04
US8642552B2 (en) 2014-02-04
ES2386058T3 (es) 2012-08-08
EP2075004A1 (en) 2009-07-01
AR063088A1 (es) 2008-12-23
AU2007304640A1 (en) 2008-04-10
MX2009003678A (es) 2009-04-22
DK2075004T3 (da) 2012-05-14
ATE544462T1 (de) 2012-02-15
RU2460536C2 (ru) 2012-09-10
BRPI0719816A2 (pt) 2015-09-08
CN101573130A (zh) 2009-11-04
KR101464208B1 (ko) 2014-12-04

Similar Documents

Publication Publication Date Title
AR063088A1 (es) Uso del factor de crecimiento epidermico para la restauracion morfofuncoional de nervios perifericos en la neuropatia diabetica
ECSP12011631A (es) Composición de insulina de acción prolongada
ECSP077339A (es) Capuchón para dispositivos para la administración de fármacos
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
CO6400181A2 (es) Compuestos de tiazolopiridina moduladores de sirtuina
PE20140105A1 (es) Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
MX382411B (es) Soluciones midriáticas y antiinflamatorias inyectables, estables y libres de conservantes.
MX2020008468A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
UY31170A1 (es) Compuestos moduladores de sirtuina
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
AR083651A1 (es) Composiciones de brimonidina en gel y metodos de uso
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
NI201100117A (es) Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2.
PE20180026A1 (es) Composicion topica curativa
MX2023012851A (es) Métodos de tratamiento y seguimiento de la enfermedad de parkinson.
CL2012000351A1 (es) Compuestos derivados de azetidin-2-ona; con un efecto inhibidor sobre el colesterol; procedimiento para preparar los compuestos; compuestos intermediarios; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos.
UY35695A (es) Composicion para el tratamiento contra el envejecimiento de la piel
ECSP10010642A (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes

Legal Events

Date Code Title Description
FG Grant of patent